scholarly journals Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER

2014 ◽  
Vol 68 (9) ◽  
pp. 1065-1073 ◽  
Author(s):  
S. A. Kaplan ◽  
L. Cardozo ◽  
S. Herschorn ◽  
L. Grenabo ◽  
M. Carlsson ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Efficacy And Safety ◽  
Tolterodine Er

scholarly journals Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies

2017 ◽  
Vol 9 (6) ◽  
pp. 137-154 ◽  
Author(s):  
Andrea Tubaro ◽  
José E. Batista ◽  
Victor W. Nitti ◽  
Sender Herschorn ◽  
Christopher R. Chapple ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Placebo Treatment ◽  
Phase Iii ◽  
Efficacy And Safety ◽  
Prostatic Enlargement ◽  
Phase Iiib ◽  
Male Patients ◽  
Micturition Frequency ◽  
Phase Iii Studies ◽  
Tolterodine Er

Background: Oral pharmacotherapies to treat overactive bladder (OAB) are used less in men despite a similar prevalence of storage symptoms as women. The efficacy and safety of once-daily mirabegron 50 mg was evaluated in male OAB patients from five phase III studies that included placebo or antimuscarinic (tolterodine ER 4 mg or solifenacin 5 mg) as a comparator. Methods: Three pooled 12-week placebo-controlled studies (mirabegron 50 mg versus placebo) and one 12-week non-inferiority phase IIIb study (BEYOND; mirabegron 50 mg versus solifenacin 5 mg) were used for efficacy (daily micturition frequency, urgency and incontinence episodes) and safety analyses. An additional 52-week active-controlled phase III safety study (mirabegron 50 mg versus tolterodine ER 4 mg) was included in the safety analysis. Male patients aged ⩾18 years with OAB for ⩾3 months were included in the analyses. Patients may also have a history of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)/benign prostatic enlargement (BPE) or concomitant use of α1-blockers. Results: In the pooled studies, mirabegron 50 mg demonstrated superiority versus placebo (treatment difference: −0.37 [95% confidence interval (CI): −0.74, −0.01]) for reducing micturition frequency; improvements in urgency and incontinence were not significantly different between mirabegron 50 mg and placebo. In BEYOND, mirabegron 50 mg was comparable with solifenacin 5 mg for reducing micturition frequency, urgency, and incontinence episodes. Mirabegron was well tolerated at 12 and 52 weeks and overall treatment-emergent adverse events (AEs) were similar to those with placebo. Conclusions: In a male OAB population with or without LUTS associated with BPH/BPE, mirabegron 50 mg provided similar improvements in urgency, frequency, and incontinence as solifenacin 5 mg, and is a well-tolerated alternative to antimuscarinics. In the three pooled 12-week studies, significant differences were not seen for urgency and incontinence versus placebo, although mirabegron 50 mg did demonstrate significant improvements versus placebo for frequency.

Web-based trial to evaluate the efficacy and safety of tolterodine ER 4mg in participants with overactive bladder: REMOTE trial

2014 ◽  
Vol 38 (2) ◽  
pp. 190-197 ◽  
Author(s):  
Miguel Orri ◽  
Craig H. Lipset ◽  
Bradly P. Jacobs ◽  
Anthony J. Costello ◽  
Steven R. Cummings
Keyword(s):  
Overactive Bladder ◽  
Efficacy And Safety ◽  
Web Based ◽  
Tolterodine Er

scholarly journals Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study

2008 ◽  
Vol 62 (11) ◽  
pp. 1675-1683 ◽  
Author(s):  
M.-S Choo ◽  
J. Z. Lee ◽  
J. B. Lee ◽  
Y.-H. Kim ◽  
H. C. Jung ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Multicentre Study ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Korean Patients ◽  
Solifenacin Succinate

Clinical Efficacy and Safety of Imidafenacin as Add-on Treatment for Persistent Overactive Bladder Symptoms Despite α-Blocker Treatment in Patients With BPH: The ADDITION STUDY

Urology ◽  
2013 ◽  
Vol 82 (4) ◽  
pp. 887-893 ◽  
Author(s):  
Masayuki Takeda ◽  
Osamu Nishizawa ◽  
Momokazu Gotoh ◽  
Masaki Yoshida ◽  
Satoru Takahashi ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Clinical Efficacy ◽  
Efficacy And Safety ◽  
Overactive Bladder Symptoms ◽  
Bladder Symptoms

scholarly journals Efficacy and Safety of Propiverine Hydrochloride for Overactive Bladder in Adult: a Systematic Review and Meta-analysis

2015 ◽  
Vol 77 (S3) ◽  
pp. 1369-1377 ◽  
Author(s):  
Wei Huang ◽  
Huantao Zong ◽  
Xin Zhou ◽  
Tao Wang ◽  
Yong Zhang
Keyword(s):  
Systematic Review ◽  
Overactive Bladder ◽  
Meta Analysis ◽  
Efficacy And Safety
Sign in / Sign up

Export Citation Format

Share Document